Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC
Qiuqiang Chen, Gang Jia, Xilin Zhang, Wenxue Ma
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsFibroblast Growth Factor Research · Lung Cancer Treatments and Mutations · Cytokine Signaling Pathways and Interactions
In the published article, there was an error in affiliation 1. Instead of “1”, it should be “3” only for the corresponding author Wenxue Ma. The correct affiliations of the authors are listed below.
Qiuqiang Chen^1^, Gang Jia^2^, Xilin Zhang^1^, Wenxue Ma^3^ **
^1^ Key Laboratory for Translational Medicine, The First Affiliated Hospital, Huzhou University, Huzhou, Zhejiang, China
^2^ Department of Medical Oncology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, Henan, China
^3^ Department of Medicine, Moores Cancer Center, and Sanford Stem Cell Institute, University of California San Diego, La Jolla, CA, United States
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.